Renflexis

September 23, 2019September 23, 2019

Patient Groups in British Columbia Criticize Mandatory Switch to Biosimilars in IBD

News

A collaboration of Canadian patient organizations said British Columbia’s (BC) decision to switch those with inflammatory bowel disease (IBD) to biosimilar drugs is short-sighted and a breach of conventional patient-physician ... Read more

August 27, 2018August 27, 2018

British Columbia Adds Renflexis, a Remicade Biosimilar for Crohn’s, UC, to Public Drug Plan

News

Renflexis (infliximab-abda), Merck’s biosimilar of Remicade (infliximab), has been added to the public drug plan of the Canadian province of British Columbia. As of Aug. 21, adults and children with Crohn’s ... Read more

April 25, 2017April 25, 2017

Renflexis, Biosimilar for Remicade to Treat Crohn’s and UC, Approved by FDA

News

Renflexis (infliximab-abda), a biosimilar of Remicade (infliximab), has been approved in the U.S. to treat a number of autoimmune diseases, including adult and pediatric Crohn’s disease and adult ulcerative colitis. Samsung Bioepis, which ... Read more